Market News / Story
Galderma (GALD) Shows 3-Year Nemluvio Efficacy in AD and PN
·
Galderma reported ARCADIA LTE data showing adults/adolescents ≥12 with early Week 16 response maintained deep skin and itch improvements with Nemluvio up to Week 152, with no new safety signals. Separate analyses in broader AD population and PN showed sustained benefits. Material Details #DetailAI Analyst View1Week 152: 80% achieved EASI-90High sustained efficacy supports long-term use and could drive adoption and sales.2Week 152: 50% achieved EASI-100Complete clearance…